

SECOND REGULAR SESSION
HOUSE COMMITTEE SUBSTITUTE 2 FOR
HOUSE BILL NO. 1472
95TH GENERAL ASSEMBLY

3978L.04C

D. ADAM CRUMBLISS, Chief Clerk

AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to the designation of controlled substances, with penalty provisions and an emergency clause.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Section 195.017, RSMo, is repealed and one new section enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

- (1) Has high potential for abuse; and
- (2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

- (1) The controlled substances listed in this subsection are included in Schedule I;
- (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:
 - (a) Acetyl-alpha-methylfentanyl;
 - (b) Acetylmethadol;
 - (c) Allylprodine;
 - (d) Alphacetylmethadol;
 - (e) Alphameprodine;
 - (f) Alphamethadol;
 - (g) Alpha-methylfentanyl;
 - (h) Alpha-methylthiofentanyl;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

- 19 (i) Benzethidine;
- 20 (j) Betacetylmethadol;
- 21 (k) Beta-hydroxyfentanyl;
- 22 (l) Beta-hydroxy-3-methylfentanyl;
- 23 (m) Betameprodine;
- 24 (n) Betamethadol;
- 25 (o) Betaprodine;
- 26 (p) Clonitazene;
- 27 (q) Dextromoramide;
- 28 (r) Diampromide;
- 29 (s) Diethylthiambutene;
- 30 (t) Difenoxyin;
- 31 (u) Dimenoxadol;
- 32 (v) Dimepheptanol;
- 33 (w) Dimethylthiambutene;
- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etoxeridine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacetylmorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;
- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;
- 52 (pp) Para-fluorofentanyl;
- 53 (qq) PEPAP;
- 54 (rr) Phenadoxone;

55 (ss) Phenampromide;

56 (tt) Phenomorphan;

57 (uu) Phenoperidine;

58 (vv) Piritramide;

59 (ww) Proheptazine;

60 (xx) Properidine;

61 (yy) Propiram;

62 (zz) Racemoramide;

63 (aaa) Thiofentanyl;

64 (bbb) Tilidine;

65 (ccc) Trimeperidine;

66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers
67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers
68 is possible within the specific chemical designation:

69 (a) Acetorphine;

70 (b) Acetyldihydrocodeine;

71 (c) Benzylmorphine;

72 (d) Codeine methylbromide;

73 (e) Codeine-N-Oxide;

74 (f) Cyprenorphine;

75 (g) Desomorphine;

76 (h) Dihydromorphine;

77 (i) Drotebanol;

78 (j) Etorphine (except hydrochloride salt);

79 (k) Heroin;

80 (l) Hydromorphanol;

81 (m) Methyldesorphine;

82 (n) Methyldihydromorphine;

83 (o) Morphine methylbromide;

84 (p) Morphine methylsulfonate;

85 (q) Morphine-N-Oxide;

86 (r) Myrophine;

87 (s) Nicocodeine;

88 (t) Nicomorphine;

89 (u) Normorphine;

90 (v) Pholcodine;

- 91 (w) Thebacon;
- 92 (4) Any material, compound, mixture or preparation which contains any quantity of the
93 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically
94 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within
95 the specific chemical designation:
- 96 (a) 4-bromo-2, 5-dimethoxyamphetamine;
- 97 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
- 98 (c) 2,5-dimethoxyamphetamine;
- 99 (d) 2,5-dimethoxy-4-ethylamphetamine;
- 100 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 101 (f) 4-methoxyamphetamine;
- 102 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
- 103 (h) 4-methyl-2, 5-dimethoxyamphetamine;
- 104 (i) 3,4-methylenedioxyamphetamine;
- 105 (j) 3,4-methylenedioxymethamphetamine;
- 106 (k) 3,4-methylenedioxy-N-ethylamphetamine;
- 107 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
- 108 (m) 3,4,5-trimethoxyamphetamine;
- 109 (n) **5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its isomers, salts, and salts**
110 **of isomers;**
- 111 (o) Alpha-ethyltryptamine;
- 112 [(o)] (p) Alpha-methyltryptamine;
- 113 [(p)] (q) Bufotenine;
- 114 (r) **Dexanabinol, (6a*S*,10a*S*)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-**
115 **yl)-6a,7,10,10a-tetrahydrobenzo[*c*]chromen-1-ol;**
- 116 [(q)] (s) Diethyltryptamine;
- 117 [(r)] (t) Dimethyltryptamine;
- 118 [(s)] (u) 5-methoxy-N,N-diisopropyltryptamine;
- 119 [(t)] (v) Ibogaine;
- 120 (w) **Indole, or 1-butyl-3(1-naphthoyl)indole;**
- 121 (x) **Indole, or 1-pentyl-3(1-naphthoyl)indole;**
- 122 [(u)] (y) Lysergic acid diethylamide;
- 123 [(v)] (z) Marijuana or marihuana;
- 124 [(w)] (aa) Mescaline;
- 125 [(x)] (bb) Parahexyl;

126 [(y)] (cc) Peyote, to include all parts of the plant presently classified botanically as
127 Lophophora Williamsii Lemaire, whether growing or not; the seeds thereof; any extract from any
128 part of such plant; and every compound, manufacture, salt, derivative, mixture or preparation of
129 the plant, its seed or extracts;

130 (dd) Phenol, CP 47, 497 & homologues, or 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-
131 methyloctan-2-yl)phenol), where side chain n=5, and homologues where side chain n-4,6,
132 or 7;

133 [(z)] (ee) N-ethyl-3-piperidyl benzilate;

134 [(aa)] (ff) N-methyl-3-piperidyl benzilate;

135 [(bb)] (gg) Psilocybin;

136 [(cc)] (hh) Psilocyn;

137 [(dd)] (ii) Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis
138 (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis
139 plant, or in the resinous extractives of such plant, or synthetic substances, derivatives, and their
140 isomers with similar chemical structure and pharmacological activity to those substances
141 contained in the plant, such as the following:

142 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;

143 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;

144 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;

145 d. Any compounds of these structures, regardless of numerical designation of atomic
146 positions covered;

147 [(ee)] (jj) Ethylamine analog of phencyclidine;

148 [(ff)] (kk) Pyrrolidine analog of phencyclidine;

149 [(gg)] (ll) Thiophene analog of phencyclidine;

150 [(hh)] (mm) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;

151 [(ii)] (nn) Salvia divinorum;

152 [(jj)] (oo) Salvinorin A;

153 (5) Any material, compound, mixture or preparation containing any quantity of the
154 following substances having a depressant effect on the central nervous system, including their
155 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of
156 isomers is possible within the specific chemical designation:

157 (a) Gamma-hydroxybutyric acid;

158 (b) Mecloqualone;

159 (c) Methaqualone;

160 (6) Any material, compound, mixture or preparation containing any quantity of the
161 following substances having a stimulant effect on the central nervous system, including their
162 salts, isomers and salts of isomers:

- 163 (a) Aminorex;
- 164 (b) N-benzylpiperazine;
- 165 (c) Cathinone;
- 166 (d) Fenethylamine;
- 167 (e) Methcathinone;
- 168 (f) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
- 169 (g) N-ethylamphetamine;
- 170 (h) N,N-dimethylamphetamine;

171 (7) A temporary listing of substances subject to emergency scheduling under federal law
172 shall include any material, compound, mixture or preparation which contains any quantity of the
173 following substances:

- 174 (a) N-(1-benzyl-4-piperidyl)-N-phenylpropanamide (benzylfentanyl), its optical isomers,
175 salts and salts of isomers;
- 176 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its
177 optical isomers, salts and salts of isomers;

178 (8) Khat, to include all parts of the plant presently classified botanically as *catha edulis*,
179 whether growing or not; the seeds thereof; any extract from any part of such plant; and every
180 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.

181 3. The department of health and senior services shall place a substance in Schedule II
182 if it finds that:

- 183 (1) The substance has high potential for abuse;
- 184 (2) The substance has currently accepted medical use in treatment in the United States,
185 or currently accepted medical use with severe restrictions; and
- 186 (3) The abuse of the substance may lead to severe psychic or physical dependence.

187 4. The controlled substances listed in this subsection are included in Schedule II:

188 (1) Any of the following substances whether produced directly or indirectly by extraction
189 from substances of vegetable origin, or independently by means of chemical synthesis, or by
190 combination of extraction and chemical synthesis:

191 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or
192 opiate, excluding apomorphine, thebaine-derived butorphanol, dextropropofol, nalbuphine,
193 nalmefene, naloxone and naltrexone, and their respective salts but including the following:

- 194 a. Raw opium;
- 195 b. Opium extracts;

- 196 c. Opium fluid;
197 d. Powdered opium;
198 e. Granulated opium;
199 f. Tincture of opium;
200 g. Codeine;
201 h. Ethylmorphine;
202 i. Etorphine hydrochloride;
203 j. Hydrocodone;
204 k. Hydromorphone;
205 l. Metopon;
206 m. Morphine;
207 n. Oxycodone;
208 o. Oxymorphone;
209 p. Thebaine;
210 (b) Any salt, compound, derivative, or preparation thereof which is chemically
211 equivalent or identical with any of the substances referred to in this subdivision, but not
212 including the isoquinoline alkaloids of opium;
213 (c) Opium poppy and poppy straw;
214 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
215 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
216 with any of these substances, but not including decocainized coca leaves or extractions which
217 do not contain cocaine or ecgonine;
218 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid
219 or powder form which contains the phenanthrene alkaloids of the opium poppy);
220 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
221 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
222 the specific chemical designation, dextropropoxyphene excepted:
223 (a) Alfentanil;
224 (b) Alphaprodine;
225 (c) Anileridine;
226 (d) Bezitramide;
227 (e) Bulk dextropropoxyphene;
228 (f) Carfentanil;
229 (g) [Butyl nitrite;
230 (h)] Dihydrocodeine;
231 [(i)] (h) Diphenoxylate;

- 232 [(j)] (i) Fentanyl;
- 233 [(k)] (j) Isomethadone;
- 234 [(l)] (k) Levo-alphaacetylmethadol;
- 235 [(m)] (l) Levomethorphan;
- 236 [(n)] (m) Levorphanol;
- 237 [(o)] (n) Metazocine;
- 238 [(p)] (o) Methadone;
- 239 [(q)] (p) Meperidine;
- 240 [(r)] (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
- 241 [(s)] (r) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--
- 242 carboxylic acid;
- 243 [(t)] (s) Pethidine (meperidine);
- 244 [(u)] (t) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 245 [(v)] (u) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 246 [(w)] (v) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 247 [(x)] (w) Phenazocine;
- 248 [(y)] (x) Piminodine;
- 249 [(z)] (y) Racemethorphan;
- 250 [(aa)] (z) Racemorphan;
- 251 [(bb)] (aa) Remifentanil;
- 252 [(cc)] (bb) Sufentanil;
- 253 **(cc) Tapentadol;**
- 254 (3) Any material, compound, mixture, or preparation which contains any quantity of the
- 255 following substances having a stimulant effect on the central nervous system:
- 256 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 257 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
- 258 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
- 259 (d) Phenmetrazine and its salts;
- 260 (e) Methylphenidate;
- 261 (4) Any material, compound, mixture, or preparation which contains any quantity of the
- 262 following substances having a depressant effect on the central nervous system, including its salts,
- 263 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers
- 264 is possible within the specific chemical designation:
- 265 (a) Amobarbital;
- 266 (b) Glutethimide;
- 267 (c) Pentobarbital;

- 268 (d) Phencyclidine;
- 269 (e) Secobarbital;
- 270 (5) Any material or compound which contains any quantity of nabilone;
- 271 (6) Any material, compound, mixture, or preparation which contains any quantity of the
- 272 following substances:
- 273 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;
- 274 (b) Immediate precursors to phencyclidine (PCP):
- 275 a. 1-phenylcyclohexylamine;
- 276 b. 1-piperidinocyclohexanecarbonitrile (PCC)[.];
- 277 **(7) Any material, compound, mixture, or preparation which contains any quantity**
- 278 **of the following alkyl nitrites:**
- 279 **(a) Amyl nitrite;**
- 280 **(b) Butyl nitrite.**
- 281 5. The department of health and senior services shall place a substance in Schedule III
- 282 if it finds that:
- 283 (1) The substance has a potential for abuse less than the substances listed in Schedules
- 284 I and II;
- 285 (2) The substance has currently accepted medical use in treatment in the United States;
- 286 and
- 287 (3) Abuse of the substance may lead to moderate or low physical dependence or high
- 288 psychological dependence.
- 289 6. The controlled substances listed in this subsection are included in Schedule III:
- 290 (1) Any material, compound, mixture, or preparation which contains any quantity of the
- 291 following substances having a potential for abuse associated with a stimulant effect on the
- 292 central nervous system:
- 293 (a) Benzphetamine;
- 294 (b) Chlorphentermine;
- 295 (c) Clortermine;
- 296 (d) Phendimetrazine;
- 297 (2) Any material, compound, mixture or preparation which contains any quantity or salt
- 298 of the following substances or salts having a depressant effect on the central nervous system:
- 299 (a) Any material, compound, mixture or preparation which contains any quantity or salt
- 300 of the following substances combined with one or more active medicinal ingredients:
- 301 a. Amobarbital;
- 302 b. Secobarbital;
- 303 c. Pentobarbital;

- 304 (b) Any suppository dosage form containing any quantity or salt of the following:
- 305 a. Amobarbital;
- 306 b. Secobarbital;
- 307 c. Pentobarbital;
- 308 (c) Any substance which contains any quantity of a derivative of barbituric acid or its
- 309 salt;
- 310 (d) Chlorhexadol;
- 311 (e) Embutramide;
- 312 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in
- 313 a drug product for which an application has been approved under Section 505 of the federal
- 314 Food, Drug, and Cosmetic Act;
- 315 (g) Ketamine, its salts, isomers, and salts of isomers;
- 316 (h) Lysergic acid;
- 317 (i) Lysergic acid amide;
- 318 (j) Methyprylon;
- 319 (k) Sulfondiethylmethane;
- 320 (l) Sulfonethylmethane;
- 321 (m) Sulfonmethane;
- 322 (n) Tiletamine and zolazepam or any salt thereof;
- 323 (3) Nalorphine;
- 324 (4) Any material, compound, mixture, or preparation containing limited quantities of any
- 325 of the following narcotic drugs or their salts:
- 326 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
- 327 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
- 328 of opium;
- 329 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
- 330 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized
- 331 therapeutic amounts;
- 332 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
- 333 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an
- 334 isoquinoline alkaloid of opium;
- 335 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
- 336 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic
- 337 ingredients in recognized therapeutic amounts;

338 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more
339 than ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in
340 recognized therapeutic amounts;

341 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters
342 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic
343 ingredients in recognized therapeutic amounts;

344 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per
345 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more
346 active nonnarcotic ingredients in recognized therapeutic amounts;

347 (h) Not more than fifty milligrams of morphine per one hundred milliliters or per one
348 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic
349 amounts;

350 (5) Any material, compound, mixture, or preparation containing any of the following
351 narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;

352 (6) Anabolic steroids. Any drug or hormonal substance, chemically and
353 pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and
354 dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is
355 expressly intended for administration through implants to cattle or other nonhuman species and
356 which has been approved by the Secretary of Health and Human Services for that administration.
357 If any person prescribes, dispenses, or distributes such steroid for human use, such person shall
358 be considered to have prescribed, dispensed, or distributed an anabolic steroid within the
359 meaning of this paragraph. Unless specifically excepted or unless listed in another schedule, any
360 material, compound, mixture or preparation containing any quantity of the following substances,
361 including its salts, esters and ethers:

- 362 (a) $3\beta,17$ -dihydroxy-5 α -androstane;
363 (b) $3\alpha,17\beta$ -dihydroxy-5 α -androstane;
364 (c) 5 α -androstan-3,17-dione;
365 (d) 1-androstenediol ($3\beta,17\beta$ -dihydroxy-5 α -androst-1-ene);
366 (e) 1-androstenediol ($3\alpha,17\beta$ -dihydroxy-5 α -androst-1-ene);
367 (f) 4-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-4-ene);
368 (g) 5-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-5-ene);
369 (h) 1-androstenedione ([5 α]-androst-1-en-3,17-dione);
370 (i) 4-androstenedione (androst-4-en-3,17-dione);
371 (j) 5-androstenedione (androst-5-en-3,17-dione);
372 (k) Bolasterone (7 α , 17 α -dimethyl-17 β -hydroxyandrost-4-en-3-one);
373 (l) Boldenone (17 β -hydroxyandrost-1,4,-diene-3-one);

- 374 **(m) Boldione;**
375 [(m)] **(n)** Calusterone (7 β , 17 α -dimethyl-17 β -hydroxyandrost-4-en-3-one);
376 [(n)] **(o)** Clostebol (4-chloro-17 β -hydroxyandrost-4-en-3-one);
377 [(o)] **(p)** Dehydrochloromethyltestosterone (4-chloro-17 β -hydroxy-17 α -methyl-androst-
378 1,4-dien-3-one);
379 **(q) Dexoxymethyltestosterone;**
380 [(p)] **(r)** Δ 1-dihydrotestosterone (a.k.a. '1-testosterone')(17 β -hydroxy-5 α -androst-1-en-
381 3-one);
382 [(q)] **(s)** 4-dihydrotestosterone (17 β -hydroxy-androstan-3-one);
383 [(r)] **(t)** Drostanolone (17 β -hydroxy-2 α -methyl-5 α -androstan-3-one);
384 [(s)] **(u)** Ethylestrenol (17 α -ethyl-17 β -hydroxyestr-4-ene);
385 [(t)] **(v)** Fluoxymesterone (9-fluoro-17 α -methyl-11 β ,17 β -dihydroxyandrost-4-en-3-one);
386 [(u)] **(w)** Formebolone (2-formyl-17 α -methyl-11 α ,17 β -dihydroxyandrost-1,4-dien-3-
387 one);
388 [(v)] **(x)** Furazabol (17 α -methyl-17 β -hydroxyandrostan-2,3-c-furazan);
389 [(w)] **(y)** 13 β -ethyl-17 β -hydroxygon-4-en-3-one;
390 [(x)] **(z)** 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-one);
391 [(y)] **(aa)** 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-en-3-one);
392 [(z)] **(bb)** Mestanolone (17 α -methyl-17 β -hydroxy-5-androstan-3-one);
393 [(aa)] **(cc)** Mesterolone (1 α methyl-17 β -hydroxy-[5 α]-androstan-3-one);
394 [(bb)] **(dd)** Methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one);
395 [(cc)] **(ee)** Methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-ene);
396 [(dd)] **(ff)** Methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-one);
397 [(ee)] **(gg)** 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstane);
398 [(ff)] **(hh)** 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstane);
399 [(gg)] **(ii)** 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene;
400 [(hh)] **(jj)** 17 α -methyl-4-hydroxynandrolone (17 α -methyl-4-hydroxy-17 β -hydroxyestr-4-
401 en-3-one);
402 [(ii)] **(kk)** Methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);
403 [(jj)] **(ll)** Methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9-11-trien-3-one);
404 [(kk)] **(mm)** Methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one);
405 [(ll)] **(nn)** Mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one);
406 [(mm)] **(oo)** 17 α -methyl- Δ 1-dihydrotestosterone (17 β -hydroxy-17 α -methyl-5 α -androst-
407 1-en-3-one) (a.k.a. '17- α -methyl-1-testosterone');
408 [(nn)] **(pp)** Nandrolone (17 β -hydroxyestr-4-ene-3-one);
409 [(oo)] **(qq)** 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);

410 [(pp)] (rr) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
 411 (ss) **19-nor-4,9(10)-androstedione**;
 412 [(qq)] (tt) 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene);
 413 [(rr)] (uu) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
 414 [(ss)] (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
 415 [(tt)] (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
 416 [(uu)] (xx) Norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one);
 417 [(vv)] (yy) Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
 418 [(ww)] (zz) Norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one);
 419 [(xx)] (aaa) Normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one);
 420 [(yy)] (bbb) Oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androst-3-one);
 421 [(zz)] (ccc) Oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one);
 422 [(aaa)] (ddd) Oxymethalone (17 α -methyl-2-hydroxymethylene-17 β -hydroxy-[5 α]-
 423 androst-3-one);
 424 [(bbb)] (eee) Stanozolol (17 α -methyl-17 β -hydroxy-[5 α]-androst-2-eno[3,2-c]-pyrazole);
 425 [(ccc)] (fff) Stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one);
 426 [(ddd)] (ggg) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid
 427 lactone);
 428 [(eee)] (hhh) Testosterone (17 β -hydroxyandrost-4-en-3-one);
 429 [(fff)] (iii) Tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9,11-trien-3-one);
 430 [(ggg)] (jjj) Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one);
 431 [(hhh)] (kkk) Any salt, ester, or ether of a drug or substance described or listed in this
 432 subdivision, except an anabolic steroid which is expressly intended for administration through
 433 implants to cattle or other nonhuman species and which has been approved by the Secretary of
 434 Health and Human Services for that administration;
 435 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
 436 United States Food and Drug Administration approved drug product;
 437 (8) The department of health and senior services may except by rule any compound,
 438 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions
 439 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to
 440 195.320 if the compound, mixture, or preparation contains one or more active medicinal
 441 ingredients not having a stimulant or depressant effect on the central nervous system, and if the
 442 admixtures are included therein in combinations, quantity, proportion, or concentration that
 443 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on
 444 the central nervous system.

445 7. The department of health and senior services shall place a substance in Schedule IV
446 if it finds that:

- 447 (1) The substance has a low potential for abuse relative to substances in Schedule III;
448 (2) The substance has currently accepted medical use in treatment in the United States;
449 and

450 (3) Abuse of the substance may lead to limited physical dependence or psychological
451 dependence relative to the substances in Schedule III.

452 8. The controlled substances listed in this subsection are included in Schedule IV:

453 (1) Any material, compound, mixture, or preparation containing any of the following
454 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
455 as set forth below:

456 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms
457 of atropine sulfate per dosage unit;

458 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-
459 propionoxybutane);

460 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall
461 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer
462 upon the compound, mixture or preparation valuable medicinal qualities other than those
463 possessed by the narcotic drug alone:

464 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per
465 one hundred grams;

466 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters
467 or per one hundred grams;

468 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters
469 or per one hundred grams;

470 (2) Any material, compound, mixture or preparation containing any quantity of the
471 following substances, including their salts, isomers, and salts of isomers whenever the existence
472 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

473 (a) Alprazolam;

474 (b) Barbital;

475 (c) Bromazepam;

476 (d) Camazepam;

477 (e) Chloral betaine;

478 (f) Chloral hydrate;

479 (g) Chlordiazepoxide;

480 (h) Clobazam;

- 481 (i) Clonazepam;
- 482 (j) Clorazepate;
- 483 (k) Clotiazepam;
- 484 (l) Cloxazolam;
- 485 (m) Delorazepam;
- 486 (n) Diazepam;
- 487 (o) Dichloralphenazone;
- 488 (p) Estazolam;
- 489 (q) Ethchlorvynol;
- 490 (r) Ethinamate;
- 491 (s) Ethyl loflazepate;
- 492 (t) Fludiazepam;
- 493 (u) Flunitrazepam;
- 494 (v) Flurazepam;
- 495 **(w) Fospropofol;**
- 496 [(w)] **(x)** Halazepam;
- 497 [(x)] **(y)** Haloxazolam;
- 498 [(y)] **(z)** Ketazolam;
- 499 [(z)] **(aa)** Loprazolam;
- 500 [(aa)] **(bb)** Lorazepam;
- 501 [(bb)] **(cc)** Lormetazepam;
- 502 [(cc)] **(dd)** Mebutamate;
- 503 [(dd)] **(ee)** Medazepam;
- 504 [(ee)] **(ff)** Meprobamate;
- 505 [(ff)] **(gg)** Methohexital;
- 506 [(gg)] **(hh)** Methylphenobarbital (mephobarbital);
- 507 [(hh)] **(ii)** Midazolam;
- 508 [(ii)] **(jj)** Nimetazepam;
- 509 [(jj)] **(kk)** Nitrazepam;
- 510 [(kk)] **(ll)** Nordiazepam;
- 511 [(ll)] **(mm)** Oxazepam;
- 512 [(mm)] **(nn)** Oxazolam;
- 513 [(nn)] **(oo)** Paraldehyde;
- 514 [(oo)] **(pp)** Petrichloral;
- 515 [(pp)] **(qq)** Phenobarbital;
- 516 [(qq)] **(rr)** Pinazepam;

517 [(rr)] (ss) Prazepam;

518 [(ss)] (tt) Quazepam;

519 [(tt)] (uu) Temazepam;

520 [(uu)] (vv) Tetrazepam;

521 [(vv)] (ww) Triazolam;

522 [(ww)] (xx) Zaleplon;

523 [(xx)] (yy) Zolpidem;

524 [(yy)] (zz) Zopiclone;

525 (3) Any material, compound, mixture, or preparation which contains any quantity of the
526 following substance including its salts, isomers and salts of isomers whenever the existence of
527 such salts, isomers and salts of isomers is possible: fenfluramine;

528 (4) Any material, compound, mixture or preparation containing any quantity of the
529 following substances having a stimulant effect on the central nervous system, including their
530 salts, isomers and salts of isomers:

531 (a) Cathine ((+)-norpseudoephedrine);

532 (b) Diethylpropion;

533 (c) Fencamfamin;

534 (d) Fenproporex;

535 (e) Mazindol;

536 (f) Mefenorex;

537 (g) Modafinil;

538 (h) Pemoline, including organometallic complexes and chelates thereof;

539 (i) Phentermine;

540 (j) Pipradrol;

541 (k) Sibutramine;

542 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);

543 (5) Any material, compound, mixture or preparation containing any quantity of the
544 following substance, including its salts:

545 (a) butorphanol;

546 (b) pentazocine;

547 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance
548 is the only active medicinal ingredient;

549 (7) The department of health and senior services may except by rule any compound,
550 mixture, or preparation containing any depressant substance listed in subdivision (1) of this
551 subsection from the application of all or any part of sections 195.010 to 195.320 if the
552 compound, mixture, or preparation contains one or more active medicinal ingredients not having

553 a depressant effect on the central nervous system, and if the admixtures are included therein in
554 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the
555 substances which have a depressant effect on the central nervous system.

556 9. The department of health and senior services shall place a substance in Schedule V
557 if it finds that:

558 (1) The substance has low potential for abuse relative to the controlled substances listed
559 in Schedule IV;

560 (2) The substance has currently accepted medical use in treatment in the United States;
561 and

562 (3) The substance has limited physical dependence or psychological dependence liability
563 relative to the controlled substances listed in Schedule IV.

564 10. The controlled substances listed in this subsection are included in Schedule V:

565 (1) Any compound, mixture or preparation containing any of the following narcotic
566 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set
567 forth below, which also contains one or more nonnarcotic active medicinal ingredients in
568 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal
569 qualities other than those possessed by the narcotic drug alone:

570 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than
571 twenty-five micrograms of atropine sulfate per dosage unit;

572 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per
573 one hundred grams;

574 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five
575 micrograms of atropine sulfate per dosage unit;

576 (2) Any material, compound, mixture or preparation which contains any quantity of the
577 following substance having a stimulant effect on the central nervous system including its salts,
578 isomers and salts of isomers: pyrovalerone;

579 (3) Any compound, mixture, or preparation containing any detectable quantity of
580 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,
581 mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical
582 isomers, or salts of optical isomers;

583 (4) Unless specifically exempted or excluded or unless listed in another schedule, any
584 material, compound, mixture, or preparation which contains any quantity of the following
585 substances having a depressant effect on the central nervous system, including its salts:
586 [pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid]]

587 (a) **Lacosamide;**

588 (b) **Pregabalin.**

589 11. If any compound, mixture, or preparation as specified in subdivision (3) of
590 subsection 10 of this section is dispensed, sold, or distributed in a pharmacy without a
591 prescription:

592 (1) All packages of any compound, mixture, or preparation containing any detectable
593 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine,
594 its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind
595 a pharmacy counter where the public is not permitted, and only by a registered pharmacist or
596 registered pharmacy technician; and

597 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,
598 or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers,
599 or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers
600 shall be at least eighteen years of age; and

601 (3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require
602 any person, prior to their purchasing, receiving or otherwise acquiring such compound, mixture,
603 or preparation to furnish suitable photo identification that is issued by a state or the federal
604 government or a document that, with respect to identification, is considered acceptable and
605 showing the date of birth of the person;

606 (4) The seller shall deliver the product directly into the custody of the purchaser.

607 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall
608 implement and maintain an electronic log of each transaction. Such log shall include the
609 following information:

610 (1) The name, address, and signature of the purchaser;

611 (2) The amount of the compound, mixture, or preparation purchased;

612 (3) The date and time of each purchase; and

613 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy
614 technician who dispensed the compound, mixture, or preparation to the purchaser.

615 13. Each pharmacy shall submit information regarding sales of any compound, mixture,
616 or preparation as specified in subdivision (3) of subsection 10 of this section in accordance with
617 transmission methods and frequency established by the department by regulation;

618 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities
619 greater than those specified in this chapter.

620 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products
621 in a pharmacy shall ensure that all such products are located only behind a pharmacy counter
622 where the public is not permitted.

623 16. Any person who knowingly or recklessly violates the provisions of subsections 11
624 to 15 of this section is guilty of a class A misdemeanor.

625 17. The scheduling of substances specified in subdivision (3) of subsection 10 of this
626 section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds,
627 mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound,
628 mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must
629 be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.

630 18. The manufacturer of a drug product or another interested party may apply with the
631 department of health and senior services for an exemption from this section. The department of
632 health and senior services may grant an exemption by rule from this section if the department
633 finds the drug product is not used in the illegal manufacture of methamphetamine or other
634 controlled or dangerous substances. The department of health and senior services shall rely on
635 reports from law enforcement and law enforcement evidentiary laboratories in determining if the
636 proposed product can be used to manufacture illicit controlled substances.

637 19. The department of health and senior services shall revise and republish the schedules
638 annually.

639 20. The department of health and senior services shall promulgate rules under chapter
640 536, RSMo, regarding the security and storage of Schedule V controlled substances, as described
641 in subdivision (3) of subsection 10 of this section, for distributors as registered by the department
642 of health and senior services.

643 21. Logs of transactions required to be kept and maintained by this section and section
644 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is
645 the person whose transactions are recorded in the logs.

Section B. Because immediate action is necessary to designate certain controlled
2 substances to protect the general public, section A of this act is deemed necessary for the
3 immediate preservation of the public health, welfare, peace, and safety, and is hereby declared
4 to be an emergency act within the meaning of the constitution, and section A of this act shall be
5 in full force and effect upon its passage and approval.

✓